(Q33367230)

English

Bivalirudin: a review

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

Bivalirudin: a review (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Theodore E Warkentin

1

object named as

Theodore E Warkentin

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Andreas Koster

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1349-1371

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Bivalent direct thrombin inhibitors: hirudin and bivalirudin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Kinetic mechanism for the interaction of Hirulog with thrombin.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Correlation of Point-of-Care ecarin clotting time versus activated clotting time with bivalirudin concentrations

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Hirulog-like peptide reduces balloon catheter injury induced neointima formation in rat carotid artery without increase in bleeding tendency

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Inhibition by hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth-muscle cells induced by thrombin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Pharmacology and clinical use of bivalirudin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

An Assessment of Different Filter Systems for Extracorporeal Elimination of Bivalirudin: An In Vitro Study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

A second look at bivalirudin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Predictors for heparin resistance in patients undergoing coronary artery bypass grafting.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Heparin‐induced thrombocytopenia: pathogenesis and management

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Temporal aspects of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Excessive anticoagulation and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1349

21 January 2018

Identifiers

10.1517/14656566.6.8.1349

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33367230&oldid=1946928816"